Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it ...
Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high ...
Medium on MSN
6 Cologns With Possible Cancer Risks
While most cologne is used sparingly, certain ingredients used in various scents and brands do have known links to cancer ...
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody ...
While the prospect of a seven-figure payout is tempting, 20-year-old Brenda Aubin-Vega from Quebec, Canada, decided to take ...
Listing Positions Syntholene as the First Publicly Traded Pure-Play Synthetic Fuel (eFuel) Company on any European ...
I’ve worked at the forefront of health and wellness for a long time and I’ve seen it all, this is what’s coming in 2026 – the ...
Inquirer.net on MSN
Managing diabetes risk during the Filipino holiday season
From the first notes of Christmas songs in September to the final Media Noche countdown in January, the Philippine holiday ...
Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 ...
The Independent on MSN
These are the 2026 wellness trends to know, according to experts
I’ve been a health editor for a decade, these are the 2026 wellness trends you need to know - I’ve worked at the forefront of ...
Ann Behan has 10 years-plus of experience researching, writing, and editing articles, white papers, and executing searches at the board level across various industries. Her expertise includes ...
Once-weekly semaglutide 1 mg was tied to a reduction in total daily insulin dose among adults with type 1 diabetes, researchers reported in a post hoc analysis of the ADJUST-T1D trial published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results